{
  "description": "Example Amicus medicine record for Galafold (migalastat), Amicus's first-and-only oral therapy for adults with Fabry disease who have an amenable GLA variant.",
  "medicine": {
    "medicineId": "amx-med-galafold",
    "brandName": "Galafold",
    "genericName": "migalastat",
    "drugClass": "Pharmacological Chaperone",
    "routeOfAdministration": "Oral",
    "indication": "Fabry disease",
    "patientPopulation": "Adults with Fabry disease who have a GLA gene variant that is responsive (amenable) to Galafold",
    "combinationWith": [],
    "mechanismOfAction": "Selective, reversible binding to amenable mutant forms of alpha-galactosidase A to stabilize the enzyme, facilitate lysosomal trafficking, and restore activity",
    "approvals": [
      {
        "region": "EU",
        "agency": "European Commission",
        "approvalDate": "2016-05-26"
      }
    ],
    "productSite": "https://www.galafold.com"
  }
}